BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang W, Zhong Z, Luo C, Xiao Y, Li L, Zhang X, Yang L, Xiao K, Ning Y, Chen L, Liu Q, Hu X, Zhang J, Ding X, Xiang S. The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma. Theranostics 2019;9:5497-516. [PMID: 31534499 DOI: 10.7150/thno.33800] [Cited by in Crossref: 33] [Cited by in F6Publishing: 44] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Mei Y, Chen D, He S, Ye J, Luo M, Wu Q, Huang Y. Transcription Factor ELK3 Promotes Stemness and Oxaliplatin Resistance of Glioma Cells by Regulating RNASEH2A. Horm Metab Res 2023;55:149-55. [PMID: 36638810 DOI: 10.1055/a-1981-3328] [Reference Citation Analysis]
2 Nasrolahi A, Azizidoost S, Radoszkiewicz K, Najafi S, Ghaedrahmati F, Anbiyaee O, Khoshnam SE, Farzaneh M, Uddin S. Signaling pathways governing glioma cancer stem cells behavior. Cellular Signalling 2023;101:110493. [DOI: 10.1016/j.cellsig.2022.110493] [Reference Citation Analysis]
3 Xu Y, Xu M, Li X, Weng X, Su Z, Zhang M, Tan J, Zeng H, Li X, Nie L, Gong J, Chen N, Chen X, Zhou Q. SOX9 and HMGB3 co‐operatively transactivate NANOG and promote prostate cancer progression. The Prostate 2022. [DOI: 10.1002/pros.24476] [Reference Citation Analysis]
4 Zhong L, Tan W, Yang Q, Zou Z, Zhou R, Huang Y, Qiu Z, Zheng K, Huang Z. PRRX1 promotes colorectal cancer stemness and chemoresistance via the JAK2/STAT3 axis by targeting IL-6. J Gastrointest Oncol 2022;13:2989-3008. [PMID: 36636075 DOI: 10.21037/jgo-22-1137] [Reference Citation Analysis]
5 Xu H, Zhang A, Fang C, Zhu Q, Wang W, Liu Y, Zhang Z, Wang X, Yuan L, Xu Y, Shao A, Lou M. SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma. Front Immunol 2022;13:980378. [PMID: 36531992 DOI: 10.3389/fimmu.2022.980378] [Reference Citation Analysis]
6 Yan Y, Wei W, Long S, Ye S, Yang B, Jiang J, Li X, Chen J. The role of RNA modification in the generation of acquired drug resistance in glioma. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.1032286] [Reference Citation Analysis]
7 Qi M, Sun L, Zheng L, Zhang J, Han Y, Wu F, Zhao J, Niu W, Fei M, Jiang X, Zhou M. Expression and potential role of FOSB in glioma. Front Mol Neurosci 2022;15:972615. [DOI: 10.3389/fnmol.2022.972615] [Reference Citation Analysis]
8 Wang XL, Jiao BH, Wu JL, Yang JK, Hu YH, Cui K. Mechanism of RIP2 enhancing stemness of glioma cells induces temozolomide resistance. CNS Neurosci Ther 2022;28:2319-30. [PMID: 36184801 DOI: 10.1111/cns.13981] [Reference Citation Analysis]
9 He Z, Cheng M, Hu J, Liu L, Liu P, Chen L, Cao D, Tang J. miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM). J Transl Med 2022;20:443. [PMID: 36183123 DOI: 10.1186/s12967-022-03647-6] [Reference Citation Analysis]
10 Song S, Wu H, Wang F, Jiao J, Xu L, Wang H, Tong X, Yan H. Global research trends and hotspots on glioma stem cells. Front Oncol 2022;12:926025. [DOI: 10.3389/fonc.2022.926025] [Reference Citation Analysis]
11 Wang Z, Chen G. Insights about circadian clock in glioma: From molecular pathways to therapeutic drugs. CNS Neurosci Ther 2022;28:1930-41. [PMID: 36066207 DOI: 10.1111/cns.13966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Han B, Fang T, Zhang Y, Zhang Y, Gao J, Xue Y. Association of the TGFβ gene family with microenvironmental features of gastric cancer and prediction of response to immunotherapy. Front Oncol 2022;12:920599. [DOI: 10.3389/fonc.2022.920599] [Reference Citation Analysis]
13 Zhu Z, Fang C, Xu H, Yuan L, Du Y, Ni Y, Xu Y, Shao A, Zhang A, Lou M. Anoikis resistance in diffuse glioma: The potential therapeutic targets in the future. Front Oncol 2022;12:976557. [DOI: 10.3389/fonc.2022.976557] [Reference Citation Analysis]
14 Mafi A, Rahmati A, Babaei Aghdam Z, Salami R, Salami M, Vakili O, Aghadavod E. Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment. Cell Mol Biol Lett 2022;27:65. [PMID: 35922753 DOI: 10.1186/s11658-022-00354-4] [Reference Citation Analysis]
15 Wang X, Liang J, Sun H. The Network of Tumor Microtubes: An Improperly Reactivated Neural Cell Network With Stemness Feature for Resistance and Recurrence in Gliomas. Front Oncol 2022;12:921975. [PMID: 35847909 DOI: 10.3389/fonc.2022.921975] [Reference Citation Analysis]
16 Yan Q, Fang X, Li C, Lan P, Guan X. Oncofetal proteins and cancer stem cells. Essays in Biochemistry 2022. [DOI: 10.1042/ebc20220025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Shi C, Wang S, Han J, Xi L, Li M, Li Z, Zhang H. Functional insights into Brucella transcriptional regulator ArsR. Microb Pathog 2022;:105557. [PMID: 35623565 DOI: 10.1016/j.micpath.2022.105557] [Reference Citation Analysis]
18 Li Z, Bu J, Zhu X, Zhou H, Ren K, Chu PK, Li L, Hu X, Ding X. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. Biomaterials Advances 2022;136:212761. [DOI: 10.1016/j.bioadv.2022.212761] [Reference Citation Analysis]
19 Peng Q, Wang L, Wang S, Wang C, Xue Z. MicoRNA-214-3p: a key player in CPLX2-mediated inhibition on temozolomide resistance in glioma. Neurological Research. [DOI: 10.1080/01616412.2022.2064699] [Reference Citation Analysis]
20 Wang H, Man Q, Huo F, Gao X, Lin H, Li S, Wang J, Su F, Cai, L, Shi Y, Liu, B, Bu L. STAT3 pathway in cancers: Past, present, and future. MedComm 2022;3. [DOI: 10.1002/mco2.124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
21 Su XJ, Shen BD, Wang K, Song QX, Yang X, Wu DS, Shen HX, Zhu C. Roles of the Neuron-Restrictive Silencer Factor in the Pathophysiological Process of the Central Nervous System. Front Cell Dev Biol 2022;10:834620. [PMID: 35300407 DOI: 10.3389/fcell.2022.834620] [Reference Citation Analysis]
22 Yu B, Liu L, Cai F, Peng Y, Tang X, Zeng D, Li T, Zhang F, Liang Y, Yuan X, Li J, Dai Z, Liao Q, Lv XB. The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma. Cancer Cell Int 2022;22:64. [PMID: 35135529 DOI: 10.1186/s12935-022-02443-y] [Reference Citation Analysis]
23 Zhang G, Wang B, Cheng S, Fan H, Liu S, Zhou B, Liu W, Liang R, Tang Y, Zhang Y. KDELR2 knockdown synergizes with temozolomide to induce glioma cell apoptosis through the CHOP and JNK/p38 pathways. Transl Cancer Res 2021;10:3491-506. [PMID: 35116653 DOI: 10.21037/tcr-21-869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Tang Q, Cao H, Tong N, Liu Y, Wang W, Zou Y, Xu L, Zeng Z, Xu W, Yin Z, Ma W, Wang Q. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway. Phytomedicine 2022. [DOI: 10.1016/j.phymed.2022.154016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Wang W, Shi A, Lei B, Yang K, Zhang W, An P. The Value of miR-296 and miR-517c in Evaluating the Prognosis of Patients with Glioma after Radiotherapy and Chemotherapy. J Oncol 2021;2021:6082458. [PMID: 34956365 DOI: 10.1155/2021/6082458] [Reference Citation Analysis]
26 Li H, Chen J, Liu J, Lai Y, Huang S, Zheng L, Fan N. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism. Exp Cell Res 2021;409:112892. [PMID: 34688609 DOI: 10.1016/j.yexcr.2021.112892] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
27 Li J, Chen Z, Wang X, Song H. LncRNA UCA1, miR-26a, and miR-195 in coronary heart disease patients: Correlation with stenosis degree, cholesterol levels, inflammatory cytokines, and cell adhesion molecules. J Clin Lab Anal 2021;:e24070. [PMID: 34850451 DOI: 10.1002/jcla.24070] [Reference Citation Analysis]
28 Bian Z, Ji W, Xu B, Huo Z, Huang H, Huang J, Jiao J, Shao J, Zhang X. Noncoding RNAs involved in the STAT3 pathway in glioma. Cancer Cell Int 2021;21:445. [PMID: 34425834 DOI: 10.1186/s12935-021-02144-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
29 Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer 2021;1876:188616. [PMID: 34419533 DOI: 10.1016/j.bbcan.2021.188616] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 8.5] [Reference Citation Analysis]
30 Wang Y, Liu YY, Chen MB, Cheng KW, Qi LN, Zhang ZQ, Peng Y, Li KR, Liu F, Chen G, Cao C. Neuronal-driven glioma growth requires Gαi1 and Gαi3. Theranostics 2021;11:8535-49. [PMID: 34373757 DOI: 10.7150/thno.61452] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
31 Feng X, Xue F, He G, Ni Q, Huang S. Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL‑6/JAK/STAT3‑mediated PD‑L1 activity. Int J Mol Med 2021;48:165. [PMID: 34278452 DOI: 10.3892/ijmm.2021.4998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Jin J, Zhou F, Zhu J, Zeng W, Liu Y. MiR-26a inhibits the inflammatory response of microglia by targeting HMGA2 in intracerebral hemorrhage. J Int Med Res 2020;48:300060520929615. [PMID: 32588686 DOI: 10.1177/0300060520929615] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
33 Ding C, Yi X, Chen X, Wu Z, You H, Chen X, Zhang G, Sun Y, Bu X, Wu X, Lin Z, Gu J, Lin Y, Kang D. Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma. J Exp Clin Cancer Res 2021;40:164. [PMID: 33975615 DOI: 10.1186/s13046-021-01942-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
34 Bi CL, Liu JF, Zhang MY, Lan S, Yang ZY, Fang JS. LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p/MAP3K1 axis. Biosci Rep 2020;40:BSR20201111. [PMID: 33057597 DOI: 10.1042/BSR20201111] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
35 Gao XY, Zang J, Zheng MH, Zhang YF, Yue KY, Cao XL, Cao Y, Li XX, Han H, Jiang XF, Liang L. Temozolomide Treatment Induces HMGB1 to Promote the Formation of Glioma Stem Cells via the TLR2/NEAT1/Wnt Pathway in Glioblastoma. Front Cell Dev Biol 2021;9:620883. [PMID: 33614649 DOI: 10.3389/fcell.2021.620883] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
36 Khan I, Baig MH, Mahfooz S, Rahim M, Karacam B, Elbasan EB, Ulasov I, Dong JJ, Hatiboglu MA. Deciphering the Role of Autophagy in Treatment of Resistance Mechanisms in Glioblastoma. Int J Mol Sci 2021;22:1318. [PMID: 33525678 DOI: 10.3390/ijms22031318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
37 Hou Y, Sun B, Liu W, Yu B, Shi Q, Luo F, Bai Y, Feng H. Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling. Theranostics 2021;11:555-66. [PMID: 33391492 DOI: 10.7150/thno.49250] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
38 Zhong C, Tao B, Tang F, Yang X, Peng T, You J, Xia K, Xia X, Chen L, Peng L. Remodeling cancer stemness by collagen/fibronectin via the AKT and CDC42 signaling pathway crosstalk in glioma. Theranostics 2021;11:1991-2005. [PMID: 33408794 DOI: 10.7150/thno.50613] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
39 Fares J, Kanojia D, Cordero A, Ulasov I, Lesniak MS. Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies 2021. [DOI: 10.1016/b978-0-12-821567-8.00014-2] [Reference Citation Analysis]
40 Du J, Yan X, Mi S, Li Y, Ji H, Hou K, Ma S, Ba Y, Zhou P, Chen L, Xie R, Hu S. Identification of Prognostic Model and Biomarkers for Cancer Stem Cell Characteristics in Glioblastoma by Network Analysis of Multi-Omics Data and Stemness Indices. Front Cell Dev Biol 2020;8:558961. [PMID: 33195193 DOI: 10.3389/fcell.2020.558961] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
41 Yi R, Yang S, Lin X, Zhong L, Liao Y, Hu Z, Huang T, Long H, Lin J, Wu Z, Xie C, Ding S, Luo J, Luo Q, Song Y. miR-5188 augments glioma growth, migration and invasion through an SP1-modulated FOXO1-PI3K/AKT-c-JUN-positive feedback circuit. J Cell Mol Med 2020;24:11800-13. [PMID: 32902145 DOI: 10.1111/jcmm.15794] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
42 Alemohammad H, Asadzadeh Z, Motafakker Azad R, Hemmat N, Najafzadeh B, Vasefifar P, Najafi S, Baradaran B. Signaling pathways and microRNAs, the orchestrators of NANOG activity during cancer induction. Life Sci 2020;260:118337. [PMID: 32841661 DOI: 10.1016/j.lfs.2020.118337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
43 Zhang F, Liu R, Zhang H, Liu C, Liu C, Lu Y. Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells. BMC Cancer 2020;20:673. [PMID: 32682409 DOI: 10.1186/s12885-020-07155-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
44 Martelli C, King A, Simon T, Giamas G. Graphene-Induced Transdifferentiation of Cancer Stem Cells as a Therapeutic Strategy against Glioblastoma. ACS Biomater Sci Eng 2020;6:3258-69. [PMID: 33463176 DOI: 10.1021/acsbiomaterials.0c00197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
45 López-Valero I, Dávila D, González-Martínez J, Salvador-Tormo N, Lorente M, Saiz-Ladera C, Torres S, Gabicagogeascoa E, Hernández-Tiedra S, García-Taboada E, Mendiburu-Eliçabe M, Rodríguez-Fornés F, Sánchez-Domínguez R, Segovia JC, Sánchez-Gómez P, Matheu A, Sepúlveda JM, Velasco G. Midkine signaling maintains the self-renewal and tumorigenic capacity of glioma initiating cells. Theranostics 2020;10:5120-36. [PMID: 32308772 DOI: 10.7150/thno.41450] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
46 Guo G, Liu J, Ren Y, Mao X, Hao Y, Zhong C, Chen X, Wang X, Wu Y, Lian S, Mei L, Zhao Y. FRAT1 Enhances the Proliferation and Tumorigenesis of CD133+Nestin+ Glioma Stem Cells In Vitro and In Vivo. J Cancer 2020;11:2421-30. [PMID: 32201513 DOI: 10.7150/jca.37622] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Chen X, Hao A, Li X, Ye K, Zhao C, Yang H, Ma H, Hu L, Zhao Z, Hu L, Ye F, Sun Q, Zhang H, Wang H, Yao X, Fang Z. Activation of JNK and p38 MAPK Mediated by ZDHHC17 Drives Glioblastoma Multiforme Development and Malignant Progression. Theranostics 2020;10:998-1015. [PMID: 31938047 DOI: 10.7150/thno.40076] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
48 Li Z, Li M, Zhang H, Wang S, Xi L, Zhang X, Yi J, Zhang H. ChIP-seq analysis of Brucella reveals transcriptional regulation of GntR. J Basic Microbiol 2020;60:149-57. [DOI: 10.1002/jobm.201900458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]